Humans ; Pneumoconiosis ; complications ; drug therapy ; Pulmonary Disease, Chronic Obstructive ; complications ; drug therapy ; Tiotropium Bromide ; therapeutic use

Benzylisoquinolines ; therapeutic use ; Calcium Channel Blockers ; therapeutic use ; Combined Modality Therapy ; Humans ; Pneumoconiosis ; drug therapy ; Tablets

Acetylcysteine ; therapeutic use ; Humans ; Pneumoconiosis ; drug therapy ; Pulmonary Disease, Chronic Obstructive ; complications ; Treatment Outcome

Objective: To analyze the safety, effectiveness, economics, innovation, suitability and accessibility of tetrandrine in the treatment of pneumoconiosis, and provide evidence-based basis for health policy decision-making and clinical practice. Methods: In July 2022, the system searched PubMed, Embase, the Cochrane Library, CNKI, Wanfang, SinoMed databases (the retrieval time was from the establishment of the database to June 30, 2022), screened the documents that meet the standards, extracted and evaluated the data, and used the "HTA checklist" developed by the International Network of Agencies for Health Technology Assessment (INAHTA) to evaluate the HTA report. AMSTAR-2 Scale was used to evaluate the quality of systematic evaluation/Meta analysis. CHEERS Scale was used to evaluate the quality of pharmacoeconomics research. The included cohort study or case-control study was evaluated with the Newcastle-Ottawa Scale. The included randomized controlled trial (RCT) studies were evaluated using the Cochrane Risk Bias Assessment Tool (Cochrane RCT) quality evaluation criteria. Comprehensive comparison and analysis based on the characteristics of the data included in the study. Results: A total of 882 related literatures were detected from the initial screening. According to relevant standards, 8 RCT studies were finally selected for analysis. Statistical results showed that basic treatment with tetrandrine could better improve FEV(1) (MD=0.13, 95%CI: 0.06-0.20, P<0.001), FEV(1)/FVC (MD=4.48, 95%CI: 0.61-8.35, P=0.02) and clinical treatment efficiency. Tetrandrine had a low incidence of adverse reactions. The affordability coefficient of tetrandrine tablets was 0.295-0.492. Conclusion: Tetrandrine can improve the clinical symptoms and pulmonary ventilation function of pneumoconiosis patients, most of the adverse reactions are mild, and the clinical application is safe.
Humans ; Pneumoconiosis/drug therapy* ; Benzylisoquinolines/therapeutic use* ; Drugs, Chinese Herbal ; Case-Control Studies

Aged ; Humans ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Pneumoconiosis ; drug therapy ; microbiology ; Tuberculosis, Multidrug-Resistant ; drug therapy ; microbiology

Adult ; Aged ; Alprostadil ; therapeutic use ; Female ; Hemorheology ; Humans ; Male ; Middle Aged ; Pneumoconiosis ; blood ; drug therapy ; physiopathology ; Respiratory Function Tests

Aged ; Anti-Bacterial Agents ; therapeutic use ; Humans ; Levofloxacin ; Middle Aged ; Ofloxacin ; therapeutic use ; Pneumoconiosis ; complications ; Tuberculosis, Pulmonary ; complications ; drug therapy

Administration, Inhalation ; Adult ; Aged ; Aged, 80 and over ; Budesonide ; therapeutic use ; Humans ; Middle Aged ; Pneumoconiosis ; drug therapy ; Treatment Outcome

Anti-Bacterial Agents ; therapeutic use ; Antitubercular Agents ; therapeutic use ; Coal Mining ; Drug Therapy, Combination ; Follow-Up Studies ; Humans ; Male ; Ofloxacin ; therapeutic use ; Pneumoconiosis ; complications ; Silicotuberculosis ; drug therapy

Anti-Asthmatic Agents ; adverse effects ; therapeutic use ; Antineoplastic Agents ; adverse effects ; therapeutic use ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Lung Diseases ; chemically induced ; Pneumoconiosis ; drug therapy